ChickenStockChickenStock

Korean disclosure

Samsung Biologics logoSamsung Biologics 207940

Samsung Biologics amended its major shareholding report on the acquisition of shares in PolyPeptide Group AG of Switzerland through a tender offer, changing the scheduled acquisition date from November 30, 2026 to December 31, 2026.

InvestmentAmended filingFiled

Unofficial English translation by ChickenStock; the Korean original prevails. Korean page · Original filing on DART ↗

Highlights

Translated AI summary

Samsung Biologics amended its major shareholding report on the acquisition of shares in Switzerland's PolyPeptide Group AG through a tender offer. The amendment changes the scheduled acquisition date from November 30, 2026 to December 31, 2026. The company said this schedule could change again depending on the progress of the tender offer and the timing of approvals from relevant authorities.

  1. The reason for the amendment is the change in the scheduled acquisition date, which moved from November 30, 2026 to December 31, 2026.

  2. The company said it set the tender offer price at CHF 44.31 per share, and an external valuation institution calculated the value of the target shares at between CHF 31.43 and 63.22 per share.

  3. As a condition of the acquisition, the company will buy the tendered shares only if they equal about 66.7% or more of the issuer's capital on a fully diluted basis; if the threshold is not met, it will not buy any of the tendered shares.

  4. The company said the scheduled acquisition date may change depending on the timing of regulatory approvals, including approvals related to business combinations and foreign investment.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Acquisition amount (KRW) (A)
KRW 2.71 trillion
Number of shares acquired
33,016,411 shares
Ownership ratio (%)
100%
As % of total assets (A/B)
24.47%
As % of equity (A/C)
36.32%
Scheduled acquisition date
December 31, 2026 (before amendment: November 30, 2026)

Filing facts

Filing type
Investment
Report name
[Amended] Decision on Acquisition of Shares in Another Company
Filed
Oct 16, 2026
Receipt number
20261016000163